Patents by Inventor Edouard M. Cantin

Edouard M. Cantin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING HERPES SIMPLEX VIRUS INFECTIONS AND RELATED DISEASES
    Publication number: 20100040601
    Abstract: A method of treatment or prophylaxis of herpes infection and associated diseases by administration of compositions comprising pooled immunoglobulins. The active component of IVIG includes sialylated IgG species. Treatment and prophylaxis of herpes infection include herpes simplex virus 1 infection, its associated encephalitis and herpes stromal keratitis.
    Type: Application
    Filed: June 10, 2009
    Publication date: February 18, 2010
    Inventors: Edouard M. Cantin, Ramakrishna Chandran, Patric Lundberg
  • Ribozyme cleavage of HIV RNA
    Patent number: 6069007
    Abstract: Ribozymes useful to cleave HIV-1 and other viral or endogenous cellular RNAs are disclosed. Also disclosed are transformed cells which express such ribozymes and human AIDS therapy involving the administration of such ribozymes.
    Type: Grant
    Filed: November 26, 1991
    Date of Patent: May 30, 2000
    Assignee: City of Hope
    Inventors: John J. Rossi, Edouard M. Cantin, John A. Zaia, Pairoj Chang
  • Ribozyme cleavage of HIV-I RNA
    Patent number: 5144019
    Abstract: Stable, catalytic efficient ribozymes useful, inter alia, to cleave HIV-I RNA or any other viral or endogenous cellular RNA, in vitro and in vivo, cells transformed with such ribozymes and the use of such ribozymes and cells for anti-AIDs therapy are disclosed.
    Type: Grant
    Filed: June 21, 1989
    Date of Patent: September 1, 1992
    Assignee: City of Hope
    Inventors: John J. Rossi, Edouard M. Cantin, John A. Zaia, Pairoj Chang
  • Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
    Patent number: 5110802
    Abstract: A method of inhibiting human immunodeficiency virus (HIV) comprising administering a therapeutically effective amount of an antiviral agent to attack the first splice acceptor site of the tat III gene of HIV.
    Type: Grant
    Filed: July 14, 1987
    Date of Patent: May 5, 1992
    Assignee: City of Hope
    Inventors: Edouard M. Cantin, John A. Zaia, R. Bruce Wallace, John J. Rossi